Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate, learn, and advocate for lung health. First Event: October 9th APAPP Know Your Nodules Event at Biodesix Head Office in Louisville, CO T ...

Core Viewpoint - Biodesix, Inc. announced a one-for-twenty reverse stock split effective September 15, 2025, aimed at reducing the number of outstanding shares and potentially improving the stock's market perception [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on May 20, 2025, with the final ratio determined by the board of directors [2]. - The number of shares will decrease from approximately 156 million to about 8 million, with adjustments for fractional shares [2]. - The reverse stock split will not change stockholders' percentage ownership interests, except for fractional shares, which will be compensated in cash [3]. Group 2: Impact on Equity Incentive Plans - The number of shares available under the Company's equity incentive plans and the exercise prices of outstanding options and warrants will be proportionately adjusted [4]. Group 3: Administrative Process - Computershare Trust Company, N.A. will act as the transfer agent, managing the transition to post-split shares without requiring action from registered stockholders [5]. - Stockholders with certificated shares will receive instructions from Computershare on how to surrender their pre-split shares [5]. Group 4: Company Overview - Biodesix is a leader in personalized diagnostics, focusing on improving clinical care and outcomes for patients, particularly in lung disease [7].

Core Insights - Biodesix has been designated as a Thermo Fisher Scientific Center of Excellence (COE), enhancing its role in advancing NGS-based diagnostics for solid tumors [1][2] - The collaboration with Thermo Fisher has led to the validation of the Oncomine Dx Express Test, which is crucial for the FDA approval of the Genexus Dx Integrated Sequencer [2][3] - Biodesix aims to expand its molecular diagnostic and NGS testing capabilities, particularly in tissue-based profiling, as part of its commitment to improving cancer diagnosis and care [3] Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly in lung disease [4] - The company offers diagnostic tests such as Nodify Lung® Nodule Risk Assessment and IQLung Cancer Treatment Guidance, which support personalized care [4] - Biodesix Development Services provide scientific, technological, and operational capabilities to biopharmaceutical and life sciences institutions [4] Thermo Fisher COE Network - The Thermo Fisher NGS COE Network collaborates with global institutions to develop and refine the Ion Torrent™ Oncomine™ solutions portfolio [5] - This network aims to accelerate oncology research and advance precision medicine through strategic alliances [5]